TranscriptAgent
Try it free
TRANSCRIPTAGENT.AI · transcript analysis

Valbiotis lance une augmentation de capital : les explications de Sébastien Peltier

Channel: Boursorama Published: 2026-06-10 04:38
Boursorama

Sébastien Peltier says Valbiotis is gaining traction in pharmacies and on its own e-commerce site, with the pharmacy channel now leading sales thanks to more listed stores, larger orders, and strong repeat purchasing. He argues the capital increase is meant mainly to fund inventory, salesforce expansion in France, and the company’s growth path toward breakeven in 2027 and more than €100m revenue by 2030.

Watch on YouTube ›

Get the market thesis, key claims, assets, contradictions, and follow-up questions from any financial video — then unlock a version personalized to your portfolio, watchlist, and favorite speakers.

Detailed summary

This interview is a straightforward update on Valbiotis’ commercial momentum and the rationale for its capital increase. Sébastien Peltier frames the core thesis as execution: the company is building a repeatable commercial model for its scientifically tested cardiometabolic supplements, and the key evidence is the acceleration in pharmacy penetration, order size, and restocking. He says Valbiotis had roughly a 50/50 split between pharmacies and e-commerce at the end of 2025, but pharmacies have now overtaken e-commerce in the first four months of 2026 because the strategic goal is to scale through the officine network. The concrete operating numbers are the heart of the discussion. Peltier says direct pharmacy customers rose from 474 at year-end 2025 to 559 by April 30, with average pharmacy orders increasing from €471 last year to €556. …

🔒 The full detailed summary continues — read all of it free with an account. Read the full summary →

Main takeaways

  1. Pharmacies are now ahead of e-commerce in the mix, driven by more store openings, larger orders, and strong restocking.
  2. Valbiotis Pro Cholestérol is the lead product because its effect is easy for consumers to understand and verify.
  3. The company says 77% of pharmacy revenue comes from repeat orders, suggesting the products are sticking once listed.
  4. The capital increase is presented mainly as working-capital and France-salesforce funding, not an Asia-funding event.
  5. Management is guiding to about €3m revenue in 2026, €25m in 2027, breakeven by end-2027, and >€100m by 2030.
  6. International partnerships, especially Asia and the Middle East, are expected to start contributing revenue, but timing is delayed by shipment/facturation lag.

Market read by horizon

Short term

Near term, the setup is a financing story with operational momentum: the raise can support inventory and sales expansion, but the stock still needs evidence that pharmacy restocking and the first Asian shipment convert into recognized revenue.

  • The capital increase is open until 24 June at €0.86 per share with DPS maintained; near-term dilution/absorption risk is the immediate setup.
Show more
  • Management says the first Asian order has already been received and will be shipped in the summer, so second-half revenue recognition is a key catalyst.
  • Watch whether pharmacy openings and restocking stay strong; current momentum depends on conversion of new points of sale into repeat orders.
Mid term

Over the next few quarters, the company’s path depends on whether broader pharmacy penetration and a larger field force keep the growth rate compounding. If that happens, the 2027 target becomes more believable; if not, the linear projection breaks quickly.

  • Over the next several quarters, the base case is continued French expansion if new product lines and greater brand awareness keep lowering the cost of pharmacy adoption.
Show more
  • The key confirmation signal is whether the company can actually expand the field force from 16 to 25 sectors and convert that into more listed pharmacies and higher basket sizes.
  • If e-commerce repeat purchase behavior remains strong while pharmacies keep contributing the majority of sales growth, the revenue trajectory can stay near management’s linear projection.
Long term

Structurally, this is a test of whether a small consumer-health/supplement company can build a durable cardiometabolic brand with repeat purchasing and international distribution. The long-term thesis is less about one product than about whether scientific positioning can become a scalable franchise.

  • Valbiotis is trying to build a multi-channel consumer health brand around cardiometabolic prevention rather than remain a single-product supplement seller.
Show more
  • The durable thesis is that if pharmacy penetration, e-commerce retention, and international licensing all compound, the business could scale far beyond its current base.
  • The structural risk is that much of the valuation case depends on sustained commercial execution and brand trust in a competitive supplement market.
Unlock the full horizon read See the full short-term, mid-term, and long-term implications with confirmation and invalidation signals. Unlock horizon read

Key claims (8)

1:35
BULLISH consumer health distribution Valbiotis

Valbiotis has shifted from a roughly 50/50 mix of pharmacy and e-commerce toward pharmacies leading sales in the first four months of 2026.

He says pharmacies overtook e-commerce in revenue mix during the period, which he ties to the strategy of expanding the officine network.

1:55
BULLISH distribution growth Valbiotis

The pharmacy network expanded from 474 direct pharmacies at year-end 2025 to 559 by April 30, while the average pharmacy order rose to €556 from €471.

These are the main operating metrics he uses to show commercial traction and larger basket sizes.

2:40
BULLISH repeat purchasing Valbiotis

77% of pharmacy revenue since the start of the year came from replenishment orders, implying the products continue to sell after initial placement.

This is the clearest argument that the model is becoming repeatable rather than one-off.

Unlock 5 more claims See the full bullish, bearish, and counter-consensus argument map extracted from the transcript. Unlock all claims

Assets discussed (5)

Valbiotis
BULLISH stock

The interview is promotional and frames the capital raise, revenue growth, and international expansion positively.

Valbiotis Pro Cholestérol
BULLISH other

Presented as the flagship product with visible efficacy and strong repeat demand.

Unlock the full asset map (3 more) See all assets mentioned, their directional bias, and the exact reasoning. Unlock asset map

Speakers

HOST Laurent GUEST Sébastien Peltier

Interview (8 Q&A)

1:00
ventes officine

Comment se poursuit la progression des ventes en officine et comment parvenez-vous à implémenter vos produits dans les différentes pharmacies ?

Les ventes en officine prennent le pas sur l'e-commerce. Fin 2025, Valbiotis était présent dans 474 officines en direct, au 30 avril 2026 elles étaient 559. Le panier moyen est passé de 471€ à 556€, et 77% du chiffre d'affaires en officine provient de commandes de réassort, avec un délai de réassort de 36 jours.

3:20
développement réseau

Est-ce qu'il est de plus en plus facile de convaincre de nouveaux points de vente à mesure que le réseau grandit ?

C'est beaucoup moins difficile qu'en 2024 quand Valbiotis était monoproduit. Depuis, le lancement de Valbiotis Pro Santé Métabolique et Valbiotis Pro Cardiocirculation a créé un effet gamme, et la notoriété commence à jouer. 2024 était très dur, 2025 était dur, 2026 est moins dur.

4:30
ventes e-commerce

Êtes-vous satisfait de la montée en puissance des ventes sur le canal e-commerce ?

Oui, Valbiotis gagne de nouveaux clients chaque jour. La part du e-commerce dans le chiffre d'affaires total diminue, mais c'est normal car 16 attachés à la promotion médicale ouvrent des officines chaque mois. Le panier moyen est passé de 86€ à 91€, et les clients qui achètent Valbiotis Pro Cholestérol prennent souvent des cures de 3 mois et renouvellent.

Unlock the full interview (5 more Q&A) Every question, answer summary, and YouTube timestamp. Unlock full Q&A

Where this transcript pushes against consensus

  • The revenue projection appears highly extrapolative given the small current base; the interview does not deeply test sensitivity if store additions or restocking soften.
  • The claim that France could exceed €100m without more salesforce growth is asserted, but the supporting math is not fully shown.
  • The conversation treats product efficacy and consumer adoption as aligned, but there is limited discussion of competitive products, pricing pressure, or regulatory/medical constraints.
  • The Asia and Middle East developments are presented positively, yet the transcript gives little detail on execution risk, margins, or contractual enforceability.

Topics

capital increasepharmacy distributione-commercecholesterol supplementinternational partnershipsAsia joint ventureMiddle East distributionsalesforce expansionrevenue guidancebreakeven target

Create your free research agent

Unlock the full claims, asset map, scores, related transcripts, follow-up questions, and AI chat — shaped around your portfolio, watchlist, favorite speakers, and risks.

  • Full claims and asset map
  • Personalized relevance to your watchlist
  • Follow-up questions you can track
  • Related transcripts from your workspace
  • AI chat about this video
Create your free research agent
TRANSCRIPTAGENT.AI